E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Recurrent pregnancy loss after assisted reproductive technology treatment |
|
E.1.1.1 | Medical condition in easily understood language |
Recurrent pregnancy loss after assisted fertility treatment |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10078356 |
E.1.2 | Term | Recurrent pregnancy loss |
E.1.2 | System Organ Class | 100000004868 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In a randomized, double-blinded placebo-controlled trial we aim to investigate whether treatment with prednisolone and IVIg before and in early pregnancy improves the chance of a live birth in women undergoing treatment with artificial reproductive technologies (ART) after previous recurrent pregnancy losses after ART. |
|
E.2.2 | Secondary objectives of the trial |
The study aims to investigate if treatment with IVIg combined with prednisolone is associated with adverse events to the women or her child, and whether the drugs can modulate leucocyte subsets in pheripheral blood. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Women with ≥ 2 consecutive pregnancy losses (miscarriages or biochemical pregnancies) ≤ gestational week 10 after ART with the present partner |
|
E.4 | Principal exclusion criteria |
BMI ≥35 Age ≥41 years Significant uterine malformation(s) Known parental balanced chromosomal translocations ≥2 previous pregnancies with fetuses with known abnormal karyotype Patients with IgA deficiency, IgA-autoantibodies or hyperprolinaemia Anti-Müllerian hormone (AMH) <4 pmol/l if the planned IVF/ICSI cycle does not imply the use of donor egg. If IVF/ICSI with egg donation is planned, a low AMH value is not an exclusion criterion. Treatment with medication interacting with prednisolone: CYP3A4-inhibitors (fx erythromycin, itraconazol, ritonavir, lopinavir), CYP3A4-inductors (fx phenobarbital, phenytoin og rifampicin), loop diuretics, thiazides, amphotericin B, beta2-agonists, antidiabetics (metformin is acceptable), interleukin-2, somatropins, anticholinergics and regular treatment with NSAIDs. Patients with moderate/severe hypertension, diabetes mellitus, heart insufficiency, severe mental disorders, Cushing syndrome, myasthenia gravis, ocular herpes simplex, pheochromocytoma, systemic sclerosis, and moderate/severe renal dysfunction. Patients with a clinical or biochemical profile indicating need for heparin or levothyroxine treatment during pregnancy (see the description below) Previous treatment with IVIg Allergy to prednisolone and/or IVIg
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the percentage of participants with ≥1 normal, viable fetus at NT scan among all participants in each treatment group, and subsequently among participants with a positive pregnancy test after embryo transfer and among all participants except participants pregnant with a fetus having a confirmed chromosomal abnormality. Furthermore, the relative risk, absolute risk reduction, and adjusted risk ratio for this primary outcome will describe the primary outcome. The primary endpoint is also measured in subgroups based on diagnosis of primary and secondary RPL, respectively, i.e., no prior birth or a history of ≥1 previous birth after 22 weeks prior to RPL diagnosis.
The primary analyses will be undertaken as 1. an Intention-to-Treat (ITT) analysis, including all patients who were allocated to either active or placebo treatment at the start of the ART cycle, even if they did not receive infusion with IVIg or albumin due to cancellation of embryo/blastocyst transfer. 2. a per-protocol (PP) analysis including patients who were randomized and received the allocated infusion of study medicine at embryo/blastocyst transfer and had this transfer performed. (excluded: : A verified complete or partial mola or ectopic pregnancy or an induced abortion after ET for social or genetic reason)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The true measure for success in this trial is the birth of a healthy child at term with no significant adverse effects for the mother. However, the randomization code will be broken and the trial unblinded already when the last participant has completed the questionnaire after the nuchal scan in gestational week 14. This allows the research group to start data analysis, but final publication will await last delivery in order to include Intention-to-Treat and Per Protocol analyses with full perinatal data. |
|
E.5.2 | Secondary end point(s) |
The secondary outcome is the frequency of maternal and fetal serious and non-serious adverse events/reactions, other reproductive outcomes (miscarriages with and without confirmed chromosomal abnormality, negative pregnancy tests, stillbirths, live births), perinatal outcomes (sex, birth weight, gestational age, admission to neonatal unit, congenital deformities, prematurity (<37 weeks of gestation), small for gestational age (SGA = birthweight <10th percentile), birth weight <2500 g), and pregnancy complications (preeclampsia, gestational hypertension, gestational diabetes, and instrumental delivery) in each two treatment groups. The secondary endpoint is the relative difference between groups in each of the secondary outcomes. Maternal adverse reactions and fetal adverse reactions that might be associated with the study medicine will be assessed continuously during treatment of the participants and until after birth for pregnant participants.
And lastly, the effect of study medicine on immune cells and microvesicles in the participants' blood.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The same as in the primary outcome; at the time when all patients, who become pregnant after their ART treatment, have ended their pregnancy. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study ends and randomisation code will be disclosed when the last included patient has had a miscarriage or has passed gestational week 12-13 (time of nuchal scan) with a viable foetus.This allows the research group to start data analysis, but final publication will await last delivery in order to include ITT and PP analyses with full perinatal data. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |